ArticleArthritis & rheumatology (Hoboken, N.J.)2026
Prothrombotic Activation of Platelet Pannexin-1 Channels in Antiphospholipid Syndrome.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectiveATP is released from platelets through both degranulation and pannexin-1 (PANX1) channels. ATP then activates P2X receptors to amplify platelet activation via calcium-dependent signaling. The objective of this study was to evaluate the role of platelet PANX1 channels in the pathophysiology of antiphospholipid syndrome (APS), an acquired thromboinflammatory disorder characterized by platelet-activating antiphospholipid antibodies.
methodsExtracellular ATP release was measured in platelets isolated from patients with persistently positive antiphospholipid antibodies (n = 36), patients with systemic lupus erythematosus (n = 10), and healthy controls (n = 16). In some assays, purified platelets were pretreated with the PANX inhibitor carbenoxolone. Platelet signaling, P-selectin exposure, and aggregation were assessed.
resultsBasal ATP release was significantly higher in APS platelets than in controls (P < 0.0001) and normalized in the presence of carbenoxolone (P = 0.03). Carbenoxolone also reduced platelet ATP release and surface P-selectin expression induced by thrombin (P = 0.002 and P = 0.02, respectively) and convulxin (P = 0.0001 and P = 0.0012). Control platelets stimulated with IgG from patients with APS demonstrated enhanced phosphorylation of PANX1 at tyrosine-308 (P = 0.03), which was accompanied by enhanced ATP release (P = 0.0004). APS IgG boosted ADP-induced aggregation (P = 0.0011), which was reduced by carbenoxolone (P = 0.0007). The calcium chelator BAPTA-AM decreased APS IgG-mediated ATP release (P = 0.03), P-selectin expression (P = 0.0005), and aggregation (P = 0.0007). Desensitizing P2X1 receptors with α,β-MeATP decreased APS IgG-induced P-selectin expression (P = 0.0002) and aggregation (P = 0.01).
conclusionPANX1 channels appear to be important mediators of platelet activation in APS. Agents that block PANX1 may restore platelet homeostasis and limit thrombosis without impairing hemostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.